Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation

Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation

(2012) W. D. Chey et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints

(2012) E. M. M. Quigley et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation

(2012) Satish Rao et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP4)

(2012) Yohei Norimatsu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis

(2012) Rebecca M. Lovell et al.   Clinical Gastroenterology and Hepatology

Chronic constipation: new diagnostic and treatment approaches

(2012) Brian E. Lacy et al.   Therapeutic Advances in Gastroenterology

Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation - a double-blind study

(2011) M. Simrén et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation

(2011) William D Chey et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Two Randomized Trials of Linaclotide for Chronic Constipation

(2011) Anthony J. Lembo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies

(2010) M. Camilleri et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit

(2010) Robert W. Busby et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Linaclotide Improves Abdominal Pain and Bowel Habits in a Phase IIb Study of Patients With Irritable Bowel Syndrome With Constipation

(2010) Jeffrey M. Johnston et al.   GASTROENTEROLOGY

Efficacy of Linaclotide for Patients With Chronic Constipation

(2010) Anthony J. Lembo et al.   GASTROENTEROLOGY

Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract

(2010) Alexander P. Bryant et al.   LIFE SCIENCES

Pilot Study on the Effect of Linaclotide in Patients With Chronic Constipation

(2008) Jeffrey M Johnston et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY